Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
BSX Stock Chart & Stats
$93.61
$4.44(4.82%)
At close: 4:00 PM EST
$93.61
$4.44(4.82%)
Day’s Range― - ―
52-Week Range$85.98 - $109.50
Previous CloseN/A
Volume5.49M
Average Volume (3M)9.60M
Market Cap
$138.74B
Enterprise Value$149.86B
Total Cash (Recent Filing)$1.27B
Total Debt (Recent Filing)$12.05B
Price to Earnings (P/E)50.1
Beta0.85
Next Earnings
Feb 04, 2026EPS Estimate
0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.75
Shares Outstanding1,483,019,800
10 Day Avg. Volume13,840,319
30 Day Avg. Volume9,601,897
Financial Highlights & Ratios
PEG Ratio4.27
Price to Book (P/B)6.04
Price to Sales (P/S)7.85
P/FCF Ratio49.69
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue7.74
Enterprise Value/Gross Profit11.91
Enterprise Value/Ebitda29.84
Forecast
1Y Price Target
$122.75Price Target Upside31.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Electrophysiology Product ApprovalFDA approval of the Farapoint pulsed‑field ablation catheter expands the company's electrophysiology product ecosystem and may boost procedural adoption by enabling complementary use with existing mapping and ablation tools.
Penumbra Acquisition Strategic FitAcquiring Penumbra broadens neurovascular and vascular offerings, leverages Boston Scientific's global commercial reach to scale faster growth franchises, and is expected to produce revenue expansion and integration synergies over time.
Peripheral Nerve Stimulation ExpansionAcquisition of Nalu adds a smaller, less invasive implantable generator and unique stimulation waveforms that physicians view as clinically attractive, strengthening position in the growing peripheral nerve stimulation pain market.
Bears Say
Financing And Leverage RiskFinancing the acquisition with cash and new debt increases financial leverage and raises financing risk that could limit capital flexibility for future investments or buybacks.
Gross Margin PressureGross margins face pressure from a product discontinuation and tariff headwinds that could offset favorable product mix benefits and compress profit margins.
Near-term Earnings DilutionThe transaction is expected to be slightly dilutive to adjusted earnings per share initially before integration benefits materialize, which may weigh on reported profitability metrics.
Boston Scientific News
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest stock price was $85.98 and its highest was $109.50 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $138.74B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Feb 04, 2026 which is in 6 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Oct 22, 2025. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.714 by $0.036.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.78.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,483,019,800 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.75 in its last earnings report, beating expectations of $0.714. Following the earnings report the stock price went up 3.954%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in BSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Boston Scientific Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$122.75 (31.13% Upside)
$122.75 (31.13% Upside)
Blogger Sentiment
Bullish
BSX Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 17.3%
Last 30 Days ▲ 17.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.46%
12-Months-Change
Fundamentals
Return on Equity
12.66%
Trailing 12-Months
Asset Growth
12.16%
Trailing 12-Months
Company Description
Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
BSX Company Deck
BSX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook with significant sales and EPS growth, driven by the success of key products like WATCHMAN and EP. However, there were challenges in the EMEA region and some product lines, particularly due to operational disruptions and market-specific headwinds.View all BSX earnings summariesBSX Revenue Breakdown
35.79% MedSurg
64.22% Cardiovascular
BSX Stock 12 Month Forecast
Average Price Target
$122.75
▲(31.13% Upside)
Technical Analysis
Abbott Laboratories
―
Edwards Lifesciences
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
0.16% Insiders
26.93% Mutual Funds
0.49% Other Institutional Investors
50.91% Public Companies and Individual Investors